Compare AAT & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | AVLN |
|---|---|---|
| Founded | 1967 | N/A |
| Country | United States | United States |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2010 | 2026 |
| Metric | AAT | AVLN |
|---|---|---|
| Price | $24.30 | $27.95 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | 367.5K | ★ 413.8K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $4.33 | N/A |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $303.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $24.90 |
| 52 Week High | $25.97 | $33.32 |
| Indicator | AAT | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 41.88 |
| Support Level | $23.69 | $27.22 |
| Resistance Level | $24.85 | $29.59 |
| Average True Range (ATR) | 0.49 | 1.94 |
| MACD | -0.21 | 0.21 |
| Stochastic Oscillator | 15.31 | 62.25 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.